Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Is Ovarian Cancer Being Managed According to Clinical Guidelines? Evidence From a Population-Based Clinical Audit.

Sobrero S, Pagano E, Piovano E, Bono L, Ceccarelli M, Ferrero A, Macchi C, Mistrangelo M, Patriarca S, Tripodi E, Zanetti R, Bertetto O, Ciccone G, Zola P.

Int J Gynecol Cancer. 2016 Nov;26(9):1615-1623.

PMID:
27779546
2.

Delineation of the larynx as organ at risk in radiotherapy: a contouring course within "Rete Oncologica Piemonte-Valle d'Aosta" network to reduce inter- and intraobserver variability.

Cante D, Petrucci E, Piva C, Borca VC, Sciacero P, Bertodatto M, Marta C, Franco P, Viale M, La Valle G, La Porta MR, Bertetto O; On behlaf of Rete Oncologica Piemonte-Valle d’Aosta..

Radiol Med. 2016 Nov;121(11):867-872. Epub 2016 Jul 15.

PMID:
27422528
3.

Extension of the stability of anticancer drugs in pharmaceutical practice.

Baratta F, Goffredo F, Annaratone L, Sapino A, Bertetto O, Brusa P.

Panminerva Med. 2016 Dec;58(4):349-350. Epub 2016 May 17. No abstract available.

PMID:
27187146
4.

Diabetology and oncology meet in a network model: union is strength.

Gallo M, Gentile L, Arvat E, Bertetto O, Clemente G.

Acta Diabetol. 2016 Aug;53(4):515-24. doi: 10.1007/s00592-016-0839-z. Epub 2016 Feb 10. Review.

PMID:
26862082
5.

Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).

Ricardi U, Racca P, Franco P, Munoz F, Fanchini L, Rondi N, Dongiovanni V, Gabriele P, Cassoni P, Ciuffreda L, Morino M, Filippi AR, Aglietta M, Bertetto O.

Med Oncol. 2013;30(2):581. doi: 10.1007/s12032-013-0581-0. Epub 2013 Apr 19.

PMID:
23606239
6.

Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy).

Fusco V, Galassi C, Berruti A, Ortega C, Ciuffreda L, Scoletta M, Goia F, Migliario M, Baraldi A, Boccadoro M, Loidoris A, Bertetto O.

ISRN Oncol. 2013;2013:672027. doi: 10.1155/2013/672027. Epub 2013 Feb 27.

7.

Hospital factors and patient characteristics in the treatment of colorectal cancer: a population based study.

Sacerdote C, Baldi I, Bertetto O, Dicuonzo D, Farina E, Pagano E, Rosato R, Senore C, Merletti F, Ciccone G.

BMC Public Health. 2012 Sep 12;12:775. doi: 10.1186/1471-2458-12-775.

8.

FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.

Novarino AM, Satolli MA, Chiappino I, Giacobino A, Napoletano R, Ceccarelli M, Ciccone G, Schena M, Bertetto O, Ciuffreda L.

Am J Clin Oncol. 2013 Oct;36(5):466-71. doi: 10.1097/COC.0b013e31825691c3.

PMID:
22781390
9.

Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain.

Caraceni A, Bertetto O, Labianca R, Maltoni M, Mercadante S, Varrassi G, Zaninetta G, Zucco F, Bagnasco M, Lanata L, De Conno F; Breakthrough/Episodic Pain Italian Study Group..

J Pain Symptom Manage. 2012 May;43(5):833-41. doi: 10.1016/j.jpainsymman.2011.05.018. Erratum in: J Pain Symptom Manage. 2012 Dec;44(6):944.

PMID:
22560355
10.

The effects of Reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit.

Birocco N, Guillame C, Storto S, Ritorto G, Catino C, Gir N, Balestra L, Tealdi G, Orecchia C, Vito GD, Giaretto L, Donadio M, Bertetto O, Schena M, Ciuffreda L.

Am J Hosp Palliat Care. 2012 Jun;29(4):290-4. doi: 10.1177/1049909111420859. Epub 2011 Oct 13.

PMID:
21998438
11.

Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.

Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M, Recchia F, Lissoni P, Galliano M, Testore F, Porta C, Maglie M, Dall'agata M, Fumagalli L, Ridolfi R.

Int J Oncol. 2011 Oct;39(4):1011-7. doi: 10.3892/ijo.2011.1099. Epub 2011 Jun 24.

PMID:
21720704
12.

Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.

Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O.

J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4. doi: 10.1200/JCO.2011.35.1551. Epub 2011 May 2. No abstract available.

PMID:
21537047
13.

Population-based analyses of radical cystectomy and urinary diversion for bladder cancer in northern Italy.

Fedeli U, Novara G, Galassi C, Ficarra V, Schievano E, Gilardetti M, Muto G, Bertetto O, Ciccone G, Spolaore P.

BJU Int. 2011 Oct;108(8 Pt 2):E266-71. doi: 10.1111/j.1464-410X.2011.10095.x. Epub 2011 Feb 14.

14.

Impact of initial pattern of care on hospital costs in a cohort of incident lung cancer cases.

Pagano E, Gregori D, Filippini C, Di Cuonzo D, Ruffini E, Zanetti R, Rosso S, Bertetto O, Merletti F, Ciccone G.

J Eval Clin Pract. 2012 Apr;18(2):269-75. doi: 10.1111/j.1365-2753.2010.01564.x. Epub 2010 Oct 25.

PMID:
20973875
15.

The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy.

Doni L, Perin A, Manzione L, Gebbia V, Mattioli R, Speranza GB, Latini L, Iop A, Bertetto O, Ferraù F, Pugliese P, Tralongo P, Zaniboni A, Di Costanzo F.

Crit Rev Oncol Hematol. 2011 Jan;77(1):70-7. doi: 10.1016/j.critrevonc.2010.04.002. Epub 2010 May 18.

PMID:
20483635
16.

Factors affecting pattern of care and survival in a population-based cohort of non-small-cell lung cancer incident cases.

Pagano E, Filippini C, Di Cuonzo D, Ruffini E, Zanetti R, Rosso S, Bertetto O, Merletti F, Ciccone G.

Cancer Epidemiol. 2010 Aug;34(4):483-9. doi: 10.1016/j.canep.2010.04.002. Epub 2010 May 4.

PMID:
20444663
17.

Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.

Apolone G, Corli O, Negri E, Mangano S, Montanari M, Greco MT; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators., Apolone G, Bertetto O, Caraceni A, Corli O, De Conno F, Labianca R, Maltoni M, Nicora Maria F, Torri V, Zucco F.

Clin J Pain. 2009 Oct;25(8):671-82. doi: 10.1097/AJP.0b013e3181a38f9d.

PMID:
19920716
18.

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L.

BMC Cancer. 2009 Nov 3;9:388. doi: 10.1186/1471-2407-9-388.

19.

Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.

Passalacqua R, Caminiti C, Campione F, Diodati F, Todeschini R, Bisagni G, Labianca R, Dalla Chiesa M, Bracci R, Aragona M, Artioli F, Cavanna L, Masina A, De Falco F, Marzocchini B, Iacono C, Contu A, Di Costanzo F, Bertetto O, Annunziata MA.

J Clin Oncol. 2009 Apr 10;27(11):1794-9. doi: 10.1200/JCO.2007.15.0615. Epub 2009 Mar 9.

PMID:
19273715
20.

Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.

Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, Milanesi E, Bertetto O, Ciuffreda L.

Am J Clin Oncol. 2009 Feb;32(1):44-8. doi: 10.1097/COC.0b013e31817be5a9.

PMID:
19194124

Supplemental Content

Loading ...
Support Center